Drugs

, Volume 19, Issue 3, pp 195–219 | Cite as

Benzodiazepines: Clinical Pharmacology and Therapeutic Use

  • C. Bellantuono
  • V. Reggi
  • G. Tognoni
  • S. Garattini
Review Article

Keywords

Clinical Pharmacology Oxazepam Nitrazepam Clobazam Temazepam 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Achong, M.R.; Bayne, J.R.; Gerson, L.W. and Golshani, S.: Prescribing of psychoactive drugs for chronically ill elderly patients. Canadian Medical Association Journal 118: 1503–1508 (1978).PubMedGoogle Scholar
  2. Allen, M.D. and Greenblatt, D.J.: Hypnotics and sedatives; in Dukes (Ed) Side Effects of Drugs, Annual 3, pp.29–38 (Excerpta Medica, Amsterdam 1979).Google Scholar
  3. Alvan, G. and Odar-Cederlof, I.: The pharmacokinetic profile of oxazepam. Acta Psychiatrica Scandinavica (Supplementum) 274: 47–55 (1978).Google Scholar
  4. Annegers, J.F.; Hauser, W.A.; Elveback, L.R. and Kurland, L.T.: The risk of epilepsy following febrile convulsions. Neurology 29: 297–303 (1979).PubMedGoogle Scholar
  5. Athinarayanan, P.; Pierog, S.H.; Nigam, S.K. and Glass, L.: Chlordiazepoxide withdrawal in the neonate. American Journal of Obstetrics and Gynecology 124: 212–213 (1976).PubMedGoogle Scholar
  6. Balter, M.B.; Levine, J. and Manheimer, D.I.: Cross-national study of the extent of anti-anxiety/sedative drug use. New England Journal of Medicine 290: 769–774 (1974).PubMedGoogle Scholar
  7. Bergman, U.; Dahlstrom, M.; Gunnarsonn, C. and Westerholm, B.: Why are psychotropic drugs prescribed to out-patients? A methodological study. European Journal of Clinical Pharmacology 15: 249–256 (1979).PubMedGoogle Scholar
  8. Bielski, R.J. and Friedel, R.O.: Prediction of tricyclic antidepressant response. A critical review. Archives of General Psychiatry 33: 1479–1489 (1976).PubMedGoogle Scholar
  9. Blackwell, B.: Psychotropic drugs in use today. The role of diazepam in medical practice. Journal of the American Medical Association 225: 1637–1641 (1973).PubMedGoogle Scholar
  10. Boethius, G: Prescription of Drugs 1970–75 in the County of Jamtland, Sweden. Epidemiological and Clinical Pharmacological Aspects (Huddinge University Hospital, Stockholm 1977).Google Scholar
  11. Boethius, G.: Personal communication, presented at WHO Drug Utilization Research Group, Annual Meeting, Prague, August 23–25 (1979).Google Scholar
  12. Bond, A.J.; Hailly, D.M. and Lader, M.H.: Plasma concentrations of benzodiazepines. British Journal of Clinical Pharmacology 4: 51–56 (1977).PubMedGoogle Scholar
  13. Bond, A.J. and Lader, M.H.: Residual effects of hypnotics. Psychopharmacologia 25: 117–132 (1972).PubMedGoogle Scholar
  14. Bond, A.J. and Lader, M.H.: The residual effects of flurazepam. Psychopharmacologia 32: 223–235 (1973).PubMedGoogle Scholar
  15. Bond, A.J. and Lader, M.H.: Residual effects of flunitrazepam. British Journal of Clinical Pharmacology 2: 143–150 (1975).PubMedGoogle Scholar
  16. Borland, R.G and Nicholson, A.N.: Comparison of the residual effects of two benzodiazepines (nitrazepam and flurazepam hydrochloride) and pentobarbitone sodium on human performance. British Journal of Clinical Pharmacology 2: 9–17 (1975).PubMedGoogle Scholar
  17. Borland, R.G. and Nicholson, A.N.: Residual effects of potassium clorazepate, a precursor of nordiazepam. British Journal of Clinical Pharmacology 4: 86–89 (1977).PubMedGoogle Scholar
  18. Boston Collaborative Drug Surveillance Program: Clinical depression of the central nervous system due to diazepam and chlordiazepoxide in relation to cigarette smoking and age. New England Journal of Medicine 288: 277–280 (1973).Google Scholar
  19. Braestrup, C. and Squires, R.F.: Brain specific benzodiazepine receptors. British Journal of Psychiatry 133: 249–260 (1978).PubMedGoogle Scholar
  20. Brandt, R.: Passage of diazepam and desmethyldiazepam into breast milk. Arzneimittel-Forschung 26: 454–457 (1976).PubMedGoogle Scholar
  21. Brophy, J.J.: Suicide attempts with psychotherapeutic drugs. Archives of General Psychiatry 17: 652–657 (1967).PubMedGoogle Scholar
  22. Browne, T.R. and Penry, J.K.: Benzodiazepines in the treatment for epilepsy. A review. Epilepsia 14: 277–310 (1973).PubMedGoogle Scholar
  23. Castledon, C.M.; George, C.F.; Mercer, D. and Hallett, C: Increased sensitivity to nitrazepam in old age. British Medical Journal 1: 10–12 (1977).Google Scholar
  24. Clarke, C.H. and Nicholson, A.N.: Immediate and residual effects in man of the metabolites of diazepam. British Journal of Clinical Pharmacology 6: 325–331 (1978).PubMedGoogle Scholar
  25. Coates, T.J. and Thoresen, C.E.: What to use instead of sleeping pills. Journal of the American Medical Association 240: 2311–2312 (1978).PubMedGoogle Scholar
  26. Cole, A.P. and Hailey, D.M.: Diazepam and active metabolite in breast milk and their transfer to the neonate. Archives of Disease in Childhood 50: 741–742 (1975).PubMedGoogle Scholar
  27. Costa, E.; Guidotti, A. and Toffano, G.: Molecular mechanisms mediating the action of diazepam on GABA receptors. British Journal of Psychiatry 133: 239–248 (1978).PubMedGoogle Scholar
  28. Curry, S.H.: Concentration-effect relationship with major and minor tranquillizers. Clinical Pharmacology and Therapeutics 16: 192–197 (1974).PubMedGoogle Scholar
  29. Dal Bo, L.; Marcucci, F.; Perbellini, D.; Castellani, A.; Fresia, P. and Mussini, E.: Plasma levels of chlordesmethyldiazepam in humans. Submitted to Biopharmaceutics and Drug Disposition (1979).Google Scholar
  30. Dasberg, H.H.; van der Klijn, E.; Guelen, P.J.R. and van Praag, H.M.: Plasma concentrations of diazepam and its metabolite N-desmethyldiazepam in relation to anxiolytic effect. Clinical Pharmacology and Therapeutics 15: 473–483 (1974).PubMedGoogle Scholar
  31. Davis, J.M.; Bartlett, E. and Termini, B.A.: Overdosage of psychotropic drugs: A review. I. Major and minor tranquillizers. Diseases of the Nervous System 29: 157–164 (1968).PubMedGoogle Scholar
  32. De Bard, M.L.: Diazepam withdrawal syndrome: A case with psychosis, seizure and coma. American Journal of Psychiatry 136: 104–105 (1979).PubMedGoogle Scholar
  33. Dundee, J.M.; Johnston, H.M.L.; Lilbura, J.K.; Nair, S.G. and Scott, M.G.: A placebo-controlled comparison of the sedative properties of three benzodiazepines, lorazepam, flunitrazepam and fosazepam. British Journal of Clinical Pharmacology 4: 706–708 (1977).Google Scholar
  34. Editorial: Benzodiazepines — Too many similar compounds? Drug and Therapeutics Bulletin 12: 5–6 (1974).Google Scholar
  35. Editorial: Physical dependence on benzodiazepines? Drug and Therapeutics Bulletin 15: 85–86 (1977).Google Scholar
  36. Editorial: Therapeutic differences between benzodiazepines. Drug and Therapeutics Bulletin 16: 46–48 (1978a).Google Scholar
  37. Editorial: Temazepam for insomnia? Drug and Therapeutics Bulletin 16: 21–22 (1978b).Google Scholar
  38. Editorial: Febrile convulsions and their management. Drug and Therapeutics Bulletin 16: 97–99 (1978c).Google Scholar
  39. Editorial: Diazepam and lorazepam in anaesthesia. Drug and Therapeutics Bulletin 17: 19–20 (1979a).Google Scholar
  40. Editorial: Benzodiazepine withdrawal. Lancet I: 196 (1979b).Google Scholar
  41. Farah, F.; Taylor, W.; Rawlins, M.D. and James, O.: Hepatic drug acetylation and oxidation: Effects of aging in man. British Medical Journal 2: 155–156 (1977).PubMedGoogle Scholar
  42. Fuccella, L.M.; Bolcioni, G.; Tamassia, V.; Ferrario, L. and Tognoni, G.: Human pharmacokinetics and bioavailability of temazepam administered in soft gelatin capsules. European Journal of Clinical Pharmacology 12: 383–386 (1977).PubMedGoogle Scholar
  43. Garattini, S.; Marcucci, F.; Morselli, P.L. and Mussini, E.: The significance of measuring blood levels of benzodiazepines; in Davies and Prichard (Eds) Biological Effects of Drugs in Relation to their Plasma Concentrations, pp.211–225 (MacMillan, London 1973).Google Scholar
  44. Garattini, S.; Marcucci, F. and Mussini, E.: The metabolism and pharmacokinetics of selected benzodiazepines; in Usdin and Forrest (Eds) Psychotherapeutic Drugs — Part III, Applications, pp. 1039–1087 (M. Dekker, New York 1977).Google Scholar
  45. Ghoneim, M.M. and Korttila, K.: Pharmacokinetics of intravenous anaesthetics: implications for clinical use. Clinical Pharmacokinetics 2: 344–372 (1977).PubMedGoogle Scholar
  46. Gillberg, C.: Diazepam at the end of pregnancy grave risks to the neonate. Lakartidningen 74: 2587–2588 (1977).PubMedGoogle Scholar
  47. Gittelman-Klein, R.: Psychopharmacological treatment of anxiety disorders, mood disorders, and Tourette’s disorder in children; in Lipton; DiMascio and Killam (Eds) Psychopharmacology: A Generation of Progress, pp. 1471–1480 (Raven Press, New York 1978).Google Scholar
  48. Goldberg, H.L. and DiMascio, A.: Psychotropic drugs in pregnancy; in Lipton; DiMascio and Killam (Eds) Psychopharmacology: A Generation of Progress, pp.1047–1055 (Raven Press, New York 1978).Google Scholar
  49. Goldstein, B.J.; Brauzer, B.; Steinbook, R.M. and Jacobson, A.F.: Psychotropic drug treatment of mixed anxiety and depression in nonpsychiatric office patients: Expected and unexpected findings — comparing doxepin, chlordiazepoxide and placebo. Southern Medical Journal 66: 892–897 (1973).PubMedGoogle Scholar
  50. Gorbach, A.C.: Diazepam for eclampsia. American Journal of Obstetrics and Gynecology 102: 611–612 (1968).PubMedGoogle Scholar
  51. Gottschalk, L.A.: Pharmacokinetics of the minor tranquilizers and clinical response; in Lipton; DiMascio and Killam (Eds) Psychopharmacology: A Generation of Progress, pp.975–985 (Raven Press, New York 1978).Google Scholar
  52. Graham, P.: Management in child psychiatry: Recent trends. British Journal of Psychiatry 129: 97–108 (1976).PubMedGoogle Scholar
  53. Greenblatt, D.J. and Allen, M.D.: Toxicity of nitrazepam in the elderly: A report from the Boston Collaborative Drug Surveillance Program. British Journal of Clinical Pharmacology 5: 407–413 (1978).PubMedGoogle Scholar
  54. Greenblatt, D.J.; Allen, M.D.; Noel, B.J. and Shader, R.I.: Acute overdosage with benzodiazepine derivatives. Clinical Pharmacology and Therapeutics 21: 497–514 (1977b).PubMedGoogle Scholar
  55. Greenblatt, D.J.; Allen, M.D. and Shader, R.I.: Toxicity of highdose flurazepam in the elderly. Clinical Pharmacology and Therapeutics 21: 355–361 (1977a).PubMedGoogle Scholar
  56. Greenblatt, D.J. and Koch-Weser, J.: Clinical toxicity of chlordiazepoxide and diazepam in relation to serum albumin concentration: A report from the Boston Collaborative Drug Surveillance Program. European Journal of Clinical Pharmacology 7: 259–262 (1974).PubMedGoogle Scholar
  57. Greenblatt, D.J.; Schillings, R.T.; Kyriakopoulos, A.A.; Shader, R.I.; Sisenwine, S.F.; Knowles, J.A. and Ruelius, H.W.: Clinical pharmacokinetics of lorazepam. I. Absorption and disposition of oral l4C-lorazepam. Clinical Pharmacology and Therapeutics 20: 329–341 (1976).PubMedGoogle Scholar
  58. Greenblatt, D.J. and Shader, R.I.: Benzodiazepines in Clinical Practice (Raven Press, New York 1974).Google Scholar
  59. Greenblatt, D.J. and Shader, R.I.: Prazepam and lorazepam, two new benzodiazepines. New England Journal of Medicine 299: 1342–1344 (1978a).PubMedGoogle Scholar
  60. Greenblatt, D.J. and Shader, R.I.: Dependence, tolerance, and addiction to benzodiazepine: Clinical and pharmacokinetic considerations. Drug Metabolism Review 8: 13–28 (1978b).Google Scholar
  61. Greenblatt, D.J. and Shader, R.I.: Pharmacotherapy of anxiety with benzodiazepines and β-adrenergic blockers; in Lipton; DiMascio and Killam (Eds) Psychopharmacology: A Generation of Progress, pp. 1381–1390 (Raven Press, New York 1978c).Google Scholar
  62. Greenblatt, D.J. and Shader, R.I.: Caution on use of benzodiazepines in the elderly. New England Journal of Medicine 300: 1054–1055 (1979).Google Scholar
  63. Greenblatt, D.J.; Shader, R.I. and Koch-Weser, J.: Flurazepam hydrochloride. Clinical Pharmacology and Therapeutics 17: 1–14 (1975a).PubMedGoogle Scholar
  64. Greenblatt, D.J.; Shader, R.I. and Koch-Weser, J.: Pharmacokinetics in clinical medicine: Oxazepam versus other benzodiazepines. Diseases of the Nervous System 36: 6–13 (1975b).PubMedGoogle Scholar
  65. Greenblatt, D.J.; Shader, R.I. and Koch-Weser, J.: Psychotropic drug use in the Boston area. A report from the Boston Collaborative Drug Surveillance Program. Archives of General Psychiatry 32: 518–521 (1975c).PubMedGoogle Scholar
  66. Greenblatt, D.J. and Shader, R.J.: Treatment of the alcohol withdrawal syndrome; in Shader (Ed) Manual of Psychiatric Therapeutics, pp.211–235 (Little Brown, Boston, Mass. 1975d).Google Scholar
  67. Greenblatt, D.J.; Shader, R.I.; MacLeod, S.M. and Sellers, E.M.: Clinical pharmacokinetics of chlordiazepoxide. Clinical Pharmacokinetics 3: 381–394 (1978a).PubMedGoogle Scholar
  68. Greenblatt, D.J.; Woo, E.; Allen, M.D.; Orsulak, P.J. and Shader, R.I.: Rapid recovery from massive diazepam overdose. J. Amer. Med. Ass. 240: 1872–1874 (1978b).Google Scholar
  69. Griffiths, K.: Who needs the pills? Trends in tranquilliser prescribing in Northern Ireland, presented at WHO Drug Utilization Research Group, Annual Meeting, Prague, August 23–25, 1979.Google Scholar
  70. Grimsson, A.; Idanpaan-Heikkila, J.; Lunde, P.K.M.; Olafsson, O. and Westerholm, B.: The utilization of psychotropic drugs in Finland, Iceland, Norway and Sweden; in Bergman; Grimsson; Wahba and Westerholm (Eds) Studies in Drug Utilization (WHO Regional Publications Eur. Series, No. 8, Copenhagen 1979).Google Scholar
  71. Haefely, W.E.: Central actions of benzodiazepines: General introduction. British Journal of Psychiatry 133: 231–238 (1978).PubMedGoogle Scholar
  72. Hart, J.; Hill, H.M.; Bye, C.E.; Wilkinson, R.T. and Peck, A.W.: The effects of low doses of amylobarbitone sodium and diazepam on human performance. British Journal of Clinical Pharmacology 3: 289–298 (1976).PubMedGoogle Scholar
  73. Hartz, S.C.; Heinonen, O.P.; Shapiro, S.; Siskind, V. and Slone, D.: Antenatal exposure to meprobamate and chlordiazepoxide in relation to malformations, mental development, and childhood mortality. New England Journal of Medicine 292: 726–728 (1975).PubMedGoogle Scholar
  74. Haskell, D.S.; Gambill, J.D.; Gardos, G; McNair, D.M. and Fisher, S.: Doxepin or diazepam for anxious and anxious-depressed outpatients? Journal of Clinical Psychiatry 39: 135–139 (1978).PubMedGoogle Scholar
  75. Hollister, L.E.: Withdrawal from benzodiazepines therapy. Journal of the American Medical Association 237: 1432 (1977).PubMedGoogle Scholar
  76. Hollister, L.E.: Antianxiety drugs; Clinical Pharmacology of Psychotherapeutic Drugs, pp. 12–49 (Churchill Livingstone, New York 1978).Google Scholar
  77. Jick, H.: Adverse drug effects in relation to renal function. American Journal of Medicine 62: 514–517 (1977).PubMedGoogle Scholar
  78. Kales, A.; Scharf, M.B.; Kales, J.D. and Soldatos, C.R.: Rebound insomnia. A potential hazard following withdrawal of certain benzodiazepines. Journal of the American Medical Association 241: 1692–1695 (1979).PubMedGoogle Scholar
  79. Kangas, L.; Iisalo, E.; Kanto, J.; Lehtinen, V.; Pynnonen, S.; Ruikka, I.; Salminen, J.; Sillanpaa, M. and Syvalahti, E.: Human pharmacokinetics of nitrazepam: Effect of age and diseases. European Journal of Clinical Pharmacology 15: 163–170 (1979a).PubMedGoogle Scholar
  80. Kangas, L.; Kanto, J.; Lehtinen, V. and Salminen, J.: Long-term nitrazepam treatment in psychiatric out-patients with insomnia. Psychopharmacology 63: 63–66 (1979b).PubMedGoogle Scholar
  81. Kanto, J.: Benzodiazepines in pregnancy. Clinical Pharmacokinetics. In press (1979).Google Scholar
  82. Karim, A.K.M.B. and Evans, D.A.P.: Polymorphic acetylation of nitrazepam. Journal of Medical Genetics 13: 17–19 (1976).PubMedGoogle Scholar
  83. Keeler, M.H. and McCurdy, R.L.: Medical practice without antianxiety drugs. American Journal of Psychiatry 132: 654–655 (1975).PubMedGoogle Scholar
  84. Kesson, C.M.; Gray, J.M.B. and Lawson, D.H.: Benzodiazepine drugs in general medical patients. British Medical Journal 1: 680–682 (1976).PubMedGoogle Scholar
  85. Klotz, U.; Avant, G.R.; Hoyumpa, A.; Schenker, S. and Wilkinson, G.R.: The effects of age and liver disease on the disposition and elimination of diazepam in adult man. Journal of Clinical Investigation 55: 347–359 (1975).PubMedGoogle Scholar
  86. Klotz, U. and Muller-Seydlitz, P.: Altered elimination of desmethyldiazepam in the elderly. British Journal of Clinical Pharmacology 7: 119–120 (1979).PubMedGoogle Scholar
  87. Kraus, J.W.; Desmond, P.V.; Marshall, J.P.; Johnson, R.F.; Schenker, S. and Wilkinson, G.R.: Effects of aging and liver disease on disposition of lorazepam. Clinical Pharmacology Therapeutics 24: 411–419 (1978).Google Scholar
  88. Kyriakopoulos, A.A.; Greenblatt, D.J. and Shader, R.I.: Clinical pharmacokinetics of lorazepam: A review. Journal of Clinical Psychiatry 39(10): 16–23 (1978).PubMedGoogle Scholar
  89. Lader, M.: Antianxiety drugs: Clinical pharmacology and therapeutic use. Drugs 12: 362–373 (1976).PubMedGoogle Scholar
  90. Lader, M.: Benzodiazepines: The opium of the masses? Neuroscience 3: 159–165 (1978).PubMedGoogle Scholar
  91. Ladinsky, H.; Consolo, S.; Bellantuono, C. and Garattini, S.: Interaction of benzodiazepines with non and putative neurotransmitters in the brain; in Handbook of Biological Psychiatry (M. Dekker, New York, in press 1979).Google Scholar
  92. Lasagna, L.: The role of benzodiazepines in nonpsychiatric medical practice. American Journal of Psychiatry 134: 656–658 (1977).PubMedGoogle Scholar
  93. Linnoila, M. and Mattila, M.J.: Drug interaction on psychomotor skills related to driving: Diazepam and alcohol. European Journal of Clinical Pharmacology 5: 186–194 (1973).Google Scholar
  94. Linnoila, M.; Otterstromn S. and Anttila, M.: Serum chlordiazepoxide, diazepam and thioridazine concentrations after the simultaneous ingestion of alcohol and placebo drink. Annals of Clinical Research 6: 4–6 (1974b).PubMedGoogle Scholar
  95. Linnoila, M.; Saario, I. and Maki, M.: Effect of treatment with diazepam or lithium and alcohol on psychomotor skills related to driving. European Journal of Clinical Pharmacology 7: 337–342 (1974a).PubMedGoogle Scholar
  96. MacLeod, S.M.; Giles, H.G.; Bengert, B.; Liu, F.F. and Sellers, E.M.: Age- and gender-related differences in diazepam pharmacokinetics. Journal of Clinical Pharmacology 19: 15–19 (1979).PubMedGoogle Scholar
  97. MacLeod, S.M.; Giles, H.G.; Patzalek, G.; Thiessen, J.J. and Sellers, E.M.: Diazepam actions and plasma concentrations following ethanol ingestion. European Journal of Clinical Pharmacology 11: 345–349 (1977).PubMedGoogle Scholar
  98. Magnus, R.V.: A placebo controlled trial of Viloxazine with or without tranquillizers in depressive illness. Journal of International Medical Research 3: 207–213 (1975).PubMedGoogle Scholar
  99. Malpas, A.; Rowan, A.J.; Joyce, C.R.B. and Scott, D.F.: Persistent behavioural and electroencephalographic changes after single doses of nitrazepam and amylobarbitone sodium. British Medical Journal 2: 762–764 (1970).PubMedGoogle Scholar
  100. Mandelli, M.; Morselli, P.L.; Nordio, S.; Pardi, G.; Principi, N.; Sereni, F. and Tognoni, G.: Placental transfer of diazepam and its disposition in the newborn. Clinical Pharmacology and Therapeutics 17: 564–572 (1975).PubMedGoogle Scholar
  101. Mandelli, M.; Tognoni, G. and Garattini, S.: Clinical pharmacokinetics of diazepam. Clinical Pharmacokinetics 3: 72–91 (1978).PubMedGoogle Scholar
  102. Marks, J.: The Benzodiazepines: Use, Overuse, Misuse, Abuse. (MTP Press, London 1978).Google Scholar
  103. Mazzi, E.: Possible neonatal diazepam withdrawal: A case report. American Journal of Obstetrics and Gynecology 129: 586–587 (1977).PubMedGoogle Scholar
  104. Medical Letter on Drugs and Therapeutics, 19: 49–50 (1977): Choice of benzodiazepine for treatment of anxiety or insomnia.Google Scholar
  105. Mendels, J.: Depression: The distinction between syndrome and symptom. British Journal of Psychiatry 114: 1549d1554 (1968).Google Scholar
  106. Milkovich, L. and van den Berg, B.J.: Effects of prenatal meprobamate and chlordiazepoxide hydrochloride on human embryonic and fetal development. New England Journal of Medicine 291: 1268–1271 (1974).PubMedGoogle Scholar
  107. Mindham, R.H.S.: Hypnotics and sedatives; in Dukes (Ed.) Meyler’s Side Effects of Drugs, vol. 8, pp.64–83 (Excerpta Medica, Amsterdam 1975).Google Scholar
  108. Mohler, H. and Okada, T.: The benzodiazepine receptor in normal and pathological human brain. British Journal of Psychiatry 133: 261–268 (1978).PubMedGoogle Scholar
  109. Morland, J.; Setekleiv, J.; Haffner, J.F.W.; Stromsaethern C.E.; Danielsen, A. and Holst Wethe, G.: Combined effects of diazepam and ethanol on mental and psychomotor functions. Acta Pharmacologica et Toxicologica 34: 5–15 (1974).PubMedGoogle Scholar
  110. Morselli, P.L.: Pediatric clinical pharmacology routine monitoring or clinical trials? in Gouveia; Tognoni and van der Kleijn (Eds) Clinical Pharmacy and Clinical Pharmacology, pp.277–287 (North Holland, Amsterdam 1976).Google Scholar
  111. Morselli, P.L.; Principi, N.; Tognoni, G.; Raeli, E.; Belvedere, G.; Standen, S.M. and Sereni, F.: Diazepam elimination in premature and full term infants, and children. Journal of Perinatal Medicine 1: 133–141 (1973).PubMedGoogle Scholar
  112. Nicholson, A.N. and Stone, B.M.: Hypnotic activity of 3-hydroxy, N-desmethyldiazepam (oxazepam). British Journal of Clinical Pharmacology 5: 469–472 (1978).PubMedGoogle Scholar
  113. Nisbet, R.; Boulas, S.H. and Kantor, H.I.: Diazepam (Valium) during labor. Obstetrics and Gynecology 29. 726–729 (1967).PubMedGoogle Scholar
  114. Ochs, H.R.; Greenblatt, D.J.; Allen, M.D.; Harmatz, J.S.; Shader, R.I. and Bodem, G.: Effect of age and Billroth gastrectomy on absorption of desmethyldiazepam from clorazepate. Clinical Pharmacology and Therapeutics 26: 449–456 (1979).PubMedGoogle Scholar
  115. Oswald, I.: The why and how of hypnotic drugs. British Medical Journal 1: 1167–1168 (1979).PubMedGoogle Scholar
  116. Patrick, M.J.; Tilstone, W.J. and Reavey, P.: Diazepam and breastfeeding. Lancet I: 542–543 (1972).Google Scholar
  117. Pearson, I.B.: Hypnotics and sedatives; in Dukes (Ed) Side Effects of Drugs, Annual I, pp.21–29 (Excerpta Medica, Amsterdam 1977).Google Scholar
  118. Penry, J.K. and Newmark, M.E.: The use of antiepileptic drugs. Annals of Internal Medicine 90: 207–218 (1979).PubMedGoogle Scholar
  119. Pinder, R.M.; Brogden, R.N.; Speight, T.M. and Avery G.S.: Clonazepam: A review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs 12: 321–361 (1976).PubMedGoogle Scholar
  120. Raihle, J.A. and Papendick, V.E.: Clorazepate dipotassium; in Florey (Ed) Analytical Profiles of Drug Substances, vol. 4, pp. 91–112 (Academic Press, New York 1975).Google Scholar
  121. Randall, L.O. and Kappell, B.: Pharmacological activity of some benzodiazepines and their metabolites; in Garattini, Mussini and Randall (Eds) The Benzodiazepines, pp.27–51 (Raven Press, New York 1973).Google Scholar
  122. Raskin, A.; Schulterbrandt, J.G.; Reatig, N.; Chase, C. and McKeon, J.J.: Differential response to chlorpromazine, im-ipramine, and placebo. Archives of General Psychiatry 23: 164–173 (1970).PubMedGoogle Scholar
  123. Reidenberg, M.M.; Levy, M.; Warner, H.; Coutinho, C.B.; Schwartz, M.A.; Yu, G. and Cheripko, J.: Relationship between diazepam dose, plasma level, age, and central nervous system depression. Clinical Pharmacology and Therapeutics 23: 371–374 (1978).PubMedGoogle Scholar
  124. Rementeria, J.L. and Bhatt, K.: Withdrawal symptoms in neonates from intrauterine exposure to diazepam. Journal of Pediatrics 90: 123–126 (1977).PubMedGoogle Scholar
  125. Rey, E.; d’Athis, Ph.; Giraux, P.; de Lauture, D.; Turquais, J.M.; Chavinie, J. and Olive, G: Pharmacokinetics of clorazepate in pregnant and non-pregnant women. European Journal of Clinical Pharmacology 15: 175–180 (1979).PubMedGoogle Scholar
  126. Rickeis, K.; Gordon, P.E.; Jenkins, B.W.; Perloff, M; Sachs, T. and Stepansky, W.: Drug treatment in depressive illness. (Amitriptyline and chlordiazepoxide in two neurotic populations). Diseases of the Nervous System 31: 30–42 (1970).Google Scholar
  127. Rieder, J. and Wendt, G: Pharmacokinetics and metabolism of the hypnotic nitrazepam; in Garattini, Mussini and Randall (Eds) The Benzodiazepines, pp.99–127 (Raven Press, New York 1973).Google Scholar
  128. Roberts, R.K.; Wilkinson, G.R.; Branch, R.A. and Schenker, S.: Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (Librium). Gastroenterology 75: 479–485 (1978).PubMedGoogle Scholar
  129. Rupp, W.; Badian, M.; Christ, O.; Hajdu, P.; Kulkarni, R.D.; Taeuber, K.; Uihlein, M.; Bender, R. and Vanderbeke, O.: Pharmacokinetics of single and multiple doses of clobazam in humans. British Journal of Clinical Pharmacology 7: 51S–57S (1979).PubMedGoogle Scholar
  130. Russell, G.F.M.; Niaz Uniaza; Wakeling, A. and Slade, P.D.: Comparative double-blind trial of mianserin hydrochloride (Organon GB94) and diazepam in patients with depressive illness. British Journal of Clinical Pharmacology 5: 57S–65S (1978).PubMedGoogle Scholar
  131. Safra, M.J. and Oakley, G.P. Jr.: Association between cleft lip with or without cleft palate and prenatal exposure to diazepam. Lancet II: 478–480 (1975).Google Scholar
  132. Salkind, M.R. and Silverstone, T.: A clinical and psychometric evaluation of flurazepam. British Journal of Clinical Pharmacology 2: 223–226 (1975).PubMedGoogle Scholar
  133. Schatzberg, A.F. and Cole, J.O.: Benzodiazepines in depressive disorders. Archives of General Psychiatry 35: 1359–1365 (1978).PubMedGoogle Scholar
  134. Schmidt, R.T.; Stahl, S.M. and Spehlmann, R.: A pharmacologic study of the stiff-man syndrome. Correlation of clinical symptoms with urinary 3-methoxy-4-hydroxy-phenyl glycol excretion. Neurology 25: 622–626 (1975).PubMedGoogle Scholar
  135. Sellers, E.M.: Clinical pharmacology and therapeutics of benzodiazepines. Clinical Medical Association Journal 118: 1533–1538 (1978).Google Scholar
  136. Sellers, E.M. and Kalant, H.: Pharmacotherapy of acute and chronic alcoholism and alcohol withdrawal syndrome; in Clark and del Giudice (Eds), Principles of Psychopharmacology, 2nd. ed., pp.721–740 (Academic Press, New York 1978).Google Scholar
  137. Sellers, E.M.; MacLeod, S.M.; Greenblatt, D.J. and Giles, H.G.: Inhibition of chlordiazepoxide biotransformation by disulfiram. Clinical Research 24: 652A (1976).Google Scholar
  138. Sellers, E.M.; MacLeod, S.M.; Greenblatt, D.J. and Giles, H.G.: Influence of disulfiram and disease on benzodiazepines disposition (Abstract). Clinical Pharmacology and Therapeutics 21: 117 (1977).Google Scholar
  139. Seppala, T.; Korttila, K.; Hakkinen, S. and Linnoila, M.: Residual effects and skills related to driving after a single oral administration of diazepam, medazepam and lorazepam. British Journal of Clinical Pharmacology 3: 831–841 (1976).PubMedGoogle Scholar
  140. Seppala, T.; Linnoila, M. and Mattila, M.J.: Drugs, alcohol and driving. Drugs 17: 389–408 (1979).PubMedGoogle Scholar
  141. Shader, R.I.; Georgotas, A.; Greenblatt, D.J.; Harmatz, J.S. and Allen, M.D.: Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminium hydroxide. Clinical Pharmacology and Therapeutics 24: 308–315 (1978).PubMedGoogle Scholar
  142. Shader, R.I.; Greenblatt, D.J.; Harmatz, J.S.; Franke, K. and Koch-Weser, J.: Absorption and disposition of chlordiazepoxide in young and elderly male volunteers. Journal of Clinical Pharmacology 17: 709–718 (1977).PubMedGoogle Scholar
  143. Shapiro, A.K.: The placebo effect; in Clark and del Giudice (Eds), Principles of Psychopharmacology, pp.441–459 (Academic Press, New York 1978).Google Scholar
  144. Shull, H.J.; Wilkinson, G.R.; Johnson, R. and Schenker, S.: Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Annals of Internal Medicine 84: 420–425 (1976).PubMedGoogle Scholar
  145. Skegg, D.C.G.; Richards, S.M. and Doll, R.: Minor tranquillisers and road accidents. British Medical Journal 1: 917–919 (1979).PubMedGoogle Scholar
  146. Solomon, F.; White, C.C.; Parron, D.L. and Mendelson, W.B.: Sleeping pills, insomnia and medical practice. New England Journal of Medicine 300: 803–808 (1979).PubMedGoogle Scholar
  147. Solomon, K. and Hart, R.: Pitfalls and prospects in clinical research on antianxiety drugs: Benzodiazepines and placebo. A research review. Journal of Clinical Psychiatry 39: 823–831 (1978).PubMedGoogle Scholar
  148. Svenson, S.E. and Hamilton, R.G: A critique of overemphasis on side effects with the psychotropic drugs: An analysis of 18,000 chlordiazepoxide-treated cases. Current Therapeutics Research 8: 455–464 (1966).Google Scholar
  149. Tansella, M.; Siciliani, O.; Burti, L.; Schiavon, M.; Zimmermann-Tansella, Ch.; Gerna, M.; Tognoni, G. and Morselli, P.L.: N-Desmethyldiazepam and amylobarbitone sodium as hypnotics in anxious patients. Plasma levels, clinical efficacy and residual effects. Psychopharmacologia 41: 81–85 (1975).PubMedGoogle Scholar
  150. Tansella, M.; Zimmermann-Tansella, Ch.; Ferrario, L.; Preziati, L.; Tognoni, G. and Lader, M.: Plasma concentrations of diazepam, nordiazepam and amylobarbitone after short-term treatment of anxious patients. Pharmakopsychiatrie Neuro-Psychopharmakologie 11: 68–75 (1978).Google Scholar
  151. Thiessen, J.J.; Sellers, E.M.; Denbeigh, P. and Dolman, L.: Plasma protein binding of diazepam and tolbutamide in chronic alcoholics. Journal of Clinical Pharmacology 16: 345–351 (1976).PubMedGoogle Scholar
  152. Tomson, G.; Lunell, N.-O.; Sundwall, A. and Rane, A.: Placental passage of oxazepam and its metabolism in mother and newborn. Clinical Pharmacology and Therapeutics 25: 74–81 (1979).PubMedGoogle Scholar
  153. Uhlenhuth, E.H.; Balter, M.B. and Lipman, R.S.: Minor tranquilizers. Clinical correlates of use in an urban population. Archives of General Psychiatry 35: 650–655 (1978).PubMedGoogle Scholar
  154. Verbeeck, R.; Tjandramaga, T.B.; Verberckmoes, R. and DeSchepper, P.J.: Biotransformation and excretion of lorazepam in patients with chronic renal failure. British Journal of Clinical Pharmacology 3: 1033–1039 (1976).PubMedGoogle Scholar
  155. Vessman, J.; Alexanderson, B.; Sjoqvist, F.; Strindberg, B. and Sundwall, A.: Comparative pharmacokinetics of oxazepam and nortriptyline after single oral doses in man; in Garattini, Mussini and Randall (Eds) The Benzodiazepines, pp. 165–173 (Raven Press, New York 1973).Google Scholar
  156. Vinar, O.; Kamenicova, L.; Plechatova, H. and Stika, L.: Who do general practitioners prescribe benzodiazepine anxiolytics? Act. Nerv. Sup. (Praha) 20: 268–269 (1978).Google Scholar
  157. Volz, M.; Christ, O.; Kellner, H.-M.; Kuch, H.; Fehlhaber, H.-W.; Gantz, D.; Hajdu, P. and Cavagna, F.: Kinetics and metabolism of clobazam in animals and man. British Journal of Clinical Pharmacology 7: 41S–50S (1979).PubMedGoogle Scholar
  158. Wang, R.I.H.; Stockdale, S.L. and Hieb, E.: Hypnotic efficacy of lorazepam and flurazepam. Clinical Pharmacology and Therapeutics 19: 191–195 (1975).Google Scholar
  159. Weinstock, R.; Fisher, S.; Spillane, J.; Ise, C.; Shaw, D. and Torop, P.: Effects of protriptyline and perphenazine in neurotic depressed outpatients. Journal of Clinical Pharmacology 15: 627–630 (1975).PubMedGoogle Scholar
  160. Whitehead, W.E.; Blackwell, B. and Robinson, A.: Why physicians prescribe benzodiazepines in essential hypertension. A phase IV Study. Biological Psychiatry 12: 597–601 (1977).PubMedGoogle Scholar
  161. Whiting, B.; Lawrence, J.R.; Skellern, G.G. and Meier, J.: Effect of acute alcohol intoxication on the metabolism and plasma kinetics of chlordiazepoxide. British Journal of Clinical Pharmacology 7: 95–100 (1979).PubMedGoogle Scholar
  162. WHO Drug Utilization Research Group: Annual Meeting, Prague, August 23–25 (1979).Google Scholar
  163. Wilkinson, G.R.: The effects of liver disease and aging on the disposition of diazepam, chlordiazepoxide, oxazepam and lorazepam in man. Acta Psychiatrica Scandinavica, Supplements 274: 56–74 (1978).Google Scholar
  164. Wilson, J. and Ellis, F.R.: Oral premedication with lorazepam (Ativan): A comparison with heptabarbitone (Medomin) and diazepam (Valium). British Journal of Anaesthesia 45: 738–744 (1973).PubMedGoogle Scholar
  165. Wolf, S.M.: Controversies in the treatment of febrile convulsions. Neurology 29: 287–290 (1979).PubMedGoogle Scholar
  166. Zimmermann-Tansella, Ch.: The effects of benzodiazepines on psychological performance in normal subjects and anxious patients. PHD doctoral thesis, University of London (1979).Google Scholar
  167. Zimmermann-Tansella, Ch.; Tansella, M. and Lader, M.: The effects of chlordesmethyldiazepam on behavioral performance and subjective judgment in normal subjects. Journal of Clinical Pharmacology 16: 481–488 (1976).PubMedGoogle Scholar

Copyright information

© ADIS Press Australasia Pty Ltd 1980

Authors and Affiliations

  • C. Bellantuono
    • 1
  • V. Reggi
    • 1
  • G. Tognoni
    • 1
  • S. Garattini
    • 1
  1. 1.Istituto di Ricerche Farmacologiche ‘Mario Negri’MilanoItaly

Personalised recommendations